Non-Hodgkin Lymphoma — An Interview with Dr John P Leonard on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting (Companion Faculty Lecture)

Failed to add items

Sorry, we are unable to add the item because your shopping cart is already at capacity.

Please try again later

Please try again later

Please try again later

Please try again

Please try again

Please try again

Listen for free

View show details

Featuring a slide presentation and related discussion from Dr John P Leonard, including the following topics:

Five-year analysis of the POLARIX trial of polatuzumab vedotin with R-CHP for previously untreated diffuse large B-cell lymphoma (0:00)
Epcoritamab, glofitamab and other bispecific antibodies for large B-cell lymphoma (5:33)
Circulating tumor DNA as an early outcome predictor in patients with large B-cell lymphoma receiving second-line lisocabtagene maraleucel in the TRANSFORM study (16:44)
The bispecific antibodies mosunetuzumab and odronextamab as initial therapy for follicular lymphoma (FL) (19:27)
The Phase III inMIND trial of tafasitamab in combination with lenalidomide/rituximab for recurrent FL (22:58)
Updated results from studies of bispecific antibodies and chimeric antigen receptor T-cell therapy for relapsed/refractory FL (24:58)
Updates from the Phase III TRIANGLE and ECOG-ACRIN EA4151 trials on the role of autologous stem cell transplant in the treatment of previously untreated mantle cell lymphoma (MCL) (27:48)
Novel treatment approaches with Bruton tyrosine kinase inhibitors for patients with newly diagnosed MCL (30:53)

CME information and select publications

No reviews yet